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For dominantly inherited disorders development of gene 
therapies, targeting the primary genetic lesion has been 
impeded  by  mutational  heterogeneity.  An  example  is 
rhodopsin-linked autosomal dominant retinitis pigmen-
tosa with over 150 mutations in the rhodopsin gene. 
Validation of a mutation-independent suppression and 
replacement  gene  therapy  for  this  disorder  has  been 
undertaken. The therapy provides a means of correcting 
the genetic defect in a mutation-independent manner 
thereby circumventing the mutational diversity. Separate 
adeno-associated virus (AAV) vectors were used to deliver 
an  RNA  interference  (RNAi)-based  rhodopsin  suppres-
sor and a codon-modified rhodopsin replacement gene 
resistant to suppression due to nucleotide alterations at 
degenerate positions over the RNAi target site. Viruses 
were subretinally coinjected into P347S mice, a model of 
dominant rhodopsin-linked retinitis pigmentosa. Benefit 
in retinal function and structure detected by electroretin-
ography (ERG) and histology, respectively, was observed 
for at least 5 months. Notably, the photoreceptor cell 
layer, absent in 5-month-old untreated retinas, contained 
3–4 layers of nuclei, whereas photoreceptor ultrastruc-
ture, assessed by transmission electron microscopy (TEM) 
improved  significantly.  The  study  provides  compelling 
evidence that codelivered suppression and replacement 
is beneficial, representing a significant step toward the 
clinic.  Additionally,  dual-vector  delivery  of  combined 
therapeutics represents an exciting approach, which is 
potentially applicable to other inherited disorders.
Received 15 October 2010; accepted 8 December 2010; published online   
11 January 2011. doi:10.1038/mt.2010.293
IntroductIon
It is timely to explore gene therapies for autosomal dominantly 
inherited  rhodopsin-linked  retinitis  pigmentosa  (RHO-adRP) 
given knowledge of the genetic etiology of the disease1 and data 
suggesting  that  recombinant  adeno-associated  virus  (AAV)-
mediated subretinal gene delivery is well tolerated in the human 
eye.2–7 RHO-adRP leads to the progressive loss of photoreceptors 
and significant visual dysfunction in 1 in 30,000 people.1,8,9 The 
rhodopsin (RHO) gene is extremely highly expressed10 and con-
stitutes ~90% of the total protein content of mammalian rod outer 
segment (OS) disc membranes. Several modes of action of dif-
ferent RHO mutant proteins have been established.11 The disease 
is immensely heterogeneous with ~150 different RHO mutations 
identified  thus  far  (www.sph.uth.tmc.edu/RetNet;  www.hgmd.
cf.ac.uk).
The mutational heterogeneity present in RHO-adRP and many 
dominant genetic diseases represents a barrier to development 
of  gene-based  therapies  to  correct  the  primary  genetic  defect. 
Therefore, a mutation-independent approach involving two com-
ponents,  RNA  interference  (RNAi)-based  suppression  of  both 
mutant and wild-type RHO alleles and provision of a suppression 
resistant replacement RHO gene,12,13 is investigated here.
In  a  previous  study  of  RHO  suppression  and  replacement 
utilizing P23H mice, which simulate human RHO-adRP, a sin-
gle dual-component AAV vector was evaluated.13 The potential 
and challenges of the technology were highlighted in the study. 
Although histological benefit in the retina was obtained, func-
tional improvement was not demonstrated; probably due to the 
extremely  rapid  nature  of  the  photoreceptor  cell  degeneration 
in the P23H mouse, where photoreceptor cell loss occurs over 
approximately a 2-week period and in addition, to low levels of 
expression of the replacement RHO gene. This promoted optimi-
zation and separate evaluation of the RNAi suppression and the 
replacement components of the therapy. Additionally, these stud-
ies were performed in P347S mice (another model of RHO-adRP 
where photoreceptor cell loss is much slower given a much larger 
window of time for therapeutic intervention). RNAi suppression 
of the mutant RHO provided benefit in the presence of the endo-
genous murine rhodopsin (Rho) gene.14 In this study, Rho, resis-
tant to suppression due to natural mismatches at the RNAi target 
site, effectively functioned as a replacement gene.
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Given  the  high-expression  level  of  endogenous  Rho  it  was 
apparent that the replacement component of AAV-delivered sup-
pression and replacement required optimization. Therefore, a range 
of RHO replacement AAV vectors was generated and evaluated in 
Rho−/− mice.15 Utilization of an optimized rhodopsin promoter, 
which was far more highly expressed from AAV vectors than ear-
lier constructs, evoked electroretinographic (ERG) responses and 
resulted in the elaboration of rod OS in Rho−/− mice.15
Although generation of an efficacious dual-component gene 
therapy  (encompassing  RNAi-based  suppression  and  codon-
modified  gene  replacement)  for  dominant  disease  is  challeng-
ing, demonstration of the efficacy of each component separately 
stimulated examination of the potential benefit associated with 
combining the AAV RHO suppression and AAV RHO replace-
ment therapies. Employing two vectors rather than a single vector 
enables a further degree of control on relative levels of suppres-
sion  and  replacement.  Furthermore,  engineering  both  RNAi-
mediated suppression and optimized RHO replacement elements 
into a single AAV vector results in a transgene size at the limit for 
optimal production of AAV and therefore may result in compro-
mised infectivity, transgene expression, and viral titers.16 Hence, 
in this study, we have explored suppression and replacement of 
RHO utilizing codelivery of the two components of the therapy by 
two separate AAV vectors and demonstrate the feasibility of this 
approach in P347S mice. The results obtained provide evidence of 
significant functional benefit and therefore represent a significant 
step toward the clinic. The proof of concept obtained in this study 
supports the view that mutation-independent gene-based thera-
pies may be relevant not only for RHO-adRP but also for other 
dominant disorders. Additionally, this dual-vector dual-compo-
nent approach may be applicable to other gene therapies where 
AAV packaging size is a limiting factor or a flexible/  adaptable 
control of gene expression is desired.
results
The focus of this study was to determine whether a suppression and 
replacement gene therapy involving cosubretinal administration 
of two AAV vectors, one encoding a RHO suppressor (AAV-S) 
and the other a RHO replacement gene (AAV-R), could provide 
significant benefit in a mouse model of RHO-adRP, the P347S 
mouse.
The  working  hypothesis  was  that  coadministration  of  two 
AAVs (AAV-S and AAV-R) would result in coinfection of sig-
nificant proportions of photoreceptors. In principle, these pho-
toreceptors  should  receive  both  suppression  and  replacement 
components and therefore should function similarly to wild-type 
photoreceptors. To test the feasibility of this approach, coadmin-
istration of two AAV vectors each encoding a marker gene was 
undertaken. Both reporter genes were driven from a CMV pro-
moter. A mixture of 1.5 × 109 vector particles (vp) AAV-EGFP 
and 1.5 × 109 vp AAV-DsRed was subretinally injected into adult 
wild-type mice and retinas evaluated by histology 2 weeks later 
(n = 5). Areas of the retinas transduced by the two viruses com-
pletely overlapped as determined by microscopic analysis of whole 
mount retinas (Figure 1a–c). At the cellular level the majority of 
the transduced cells, coexpressed both markers (yellow) and only 
a few cells expressed just one marker (red or green; Figure 1d–f). 
These experiments provide evidence of significant coexpression 
following coadministration of two AAVs. The results suggest that 
a similar strategy using two AAV constructs for delivering the 
suppression and replacement components should also result in 
significant cotransduction of photoreceptors.
Initially, 6.0 × 108 vp AAV-S or an AAV expressing a non-
targeting control RNAi, AAV-C, were subretinally injected into 
contralateral eyes of P347S mouse pups, which express a human 
mutant  RHO  transgene.  AAV-S  has  previously  been  shown  to 
suppress rhodopsin mRNA by >90% in vivo (also referred to as 
siBB,13). Two weeks postinjections retinas were harvested, trans-
duced (green) cells collected by fluorescence-activated cell sorting 
and RNA extracted. Levels of mutant RHO, determined by quan-
titative real-time reverse transcription PCR (qPCR), using human 
RHO-specific  primers,  were  suppressed  by  68  ±  2.4%  (n  =  6, 
P = 0.0187) in cells transduced with AAV-S versus AAV-C, indi-
cating that efficient RHO suppression has occurred in this disease 
Figure 1  cotransduction of adeno-associated viruses (AAVs) in wild-type retinas. Eyes of wild-type mice were subretinally injected with a mixture 
of 1.5 × 109 vector particles (vp) AAV-EGFP and 1.5 × 109 vp AAV-DsRed. Two weeks postinjection eyes were fixed (n = 5), whole mounted for imag-
ing, then cryosectioned (12 μm) and processed for histology. Nuclei were counterstained with DAPI. (a–c) Representative whole mounts illustrating 
(a) enhanced green fluorescent protein (EGFP), (b) DsRed, and (c) overlay of EGFP and DsRed signals. Representative sections demonstrate significant 
coexpression (f) of (d) EGFP and (e) DsRed signals at the cellular level in the outer nuclear layer. In order to obtain a clearer view of the markers the 
DAPI (blue) signal was edited out from the ONL. Bars = 1 mm (a–c) and 25 μm (d–f). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer 
nuclear layer; RPE, retinal pigment epithelium.644  www.moleculartherapy.org  vol. 19 no. 4 apr. 2011     
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model of RHO-adRP (Figure 2a). Subsequently the resistance to 
suppression of transcripts expressed from AAV-R was determined 
in adult wild-type mice. Mixtures of either 6.0 × 108 vp AAV-S 
and 1.8 × 1010 vp AAV-R or 6.0 × 108 vp AAV-C and 1.8 × 1010 
vp AAV-R were subretinally injected into fellow eyes, total RNA 
extracted  2  weeks  postinjection  and  RNA  analyzed.  Levels  of 
RHO replacement expressed from AAV-R were determined by 
qPCR and did not differ significantly between the AAV-S and 
AAV-R or the AAV-C and AAV-R injected eyes (P = 0.814, n = 7), 
suggesting that the RHO replacement gene delivered in AAV-R is 
resistant to AAV-S suppression (Figure 2b). Additionally, subreti-
nal administration of 1.0 × 1010 vp of AAV-R was undertaken in 
adult wild-type mice (n = 8) and 2 weeks postinjection levels of 
RHO expression from AAV-R were compared to levels of expres-
sion of RHO in normal human rhodopsin (NHR) transgenic mice. 
The NHR mouse expresses a wild-type human RHO transgene at 
levels comparable with endogenous levels of mouse Rho expres-
sion and displays a wild-type phenotype.13,17 Comparison of RNA 
from whole retinas of AAV-R administered to wild-type mice and 
retinas from NHR mice demonstrated that RHO expression from 
AAV-R was ~31 ± 5% of levels observed in NHR mouse retinas. 
Notably, since only ~40% of the retina is thought to be transduced 
by AAV (Figure 2c), this suggests that overall expression levels 
of RHO from AAV-R may be similar to endogenous murine Rho 
levels and RHO levels in the NHR transgenic mouse (Figure 2c). 
Quantitative protein analysis was not undertaken as the human 
RHO-specific  antibody  used  for  immunocytochemistry  (see 
below)  is  not  suitable  for  western  blotting  or  enzyme-linked 
immunosorbent assay.
In all subsequent experiments, 5-day-old P347S mice were 
subretinally injected. In one set of experiments, right eyes were 
injected with a mixture of 6.0 × 108 vp AAV-S and 1.8 × 1010 vp 
AAV-R. Fellow left eyes received 6.0 × 108 vp of control AAV-C. 
As evaluated by 6-week postinjection ERGs, rod-isolated ampli-
tudes in eyes treated with the mixture of AAV-S and AAV-R were 
found to be 184.5 ± 65.4 μV compared to fellow eyes treated with 
control AAV-C, whereas the amplitudes were 34.9 ± 16.8 μV (P 
<0.0001, n = 17; Figure 3a,c). In 20-week postinjection ERGs, 
rod-isolated responses were 58.1 ± 19.8 μV in treated eyes com-
pared  to  16.9  ±  12.6 μV  (P  <  0.0001,  n  =  12)  in  control  eyes 
(Figure 3b,c), the latter being similar to that of uninjected eyes 
(data not shown).
In order to determine whether the improved retinal responses 
resulted from the AAV-S and AAV-R suppression and replace-
ment combination therapy or either component singly, effects 
of  AAV-R  and  AAV-S  were  assessed  separately.  To  test  the 
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Figure 2  rhodopsin mrnA expression levels. (a) Contralateral eyes 
of adult P347S mice (n = 6) expressing a mutant human RHO transgene 
were subretinally injected with 6.0 × 108 vp AAV-S or AAV-R. Two weeks 
postinjection retinas were harvested, transduced (green) cells collected 
by fluorescence-activated cell sorting (FACS) and RNA extracted. The 
level of human RHO suppression by AAV-S, determined by qPCR using 
human-specific RHO primers, was 68 ± 2.4%. (b) Adult wild-type mice 
(n = 7) were subretinally injected with a mixture of either 6.0 × 108 vp 
AAV-S and 1.8 × 1010 vp AAV-R or 6.0 × 108 vp AAV-C and 1.8 × 1010 vp 
AAV-R. Two weeks postinjection total RNA was extracted and levels of 
replacement RHO RNA determined by qPCR. No significant difference in 
replacement transcript levels was observed in eyes that received AAV-R 
and AAV-S versus AAV-R and AAV-C, indicating that no significant sup-
pression of the replacement transcript had occurred (P = 0.814). (c) Adult 
wild-type mice (n = 8) were subretinally injected with AAV-R. Total RNA 
was  extracted  2  weeks  postinjection  and  levels  of  RHO  replacement 
expression from AAV-R compared to levels of RHO in normal human rho-
dopsin (NHR) mouse retinas. Levels of RHO mRNA expression from the 
AAV-R was 31 ± 5% of levels in NHR mouse retinas.
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Figure 3  rod-derived electroretinography (erG) following combined suppression and replacement therapy. The right eyes of P5 P347S mice 
were subretinally injected with a mixture of 6.0 × 108 vp AAV-S and 1.8 × 1010 vp AAV-R whereas the left eyes were injected with 6.0 × 108 vp AAV-C. 
Six (n = 17) or twenty weeks (n = 12) postinjection, mice were dark-adapted overnight and rod-isolated ERG responses recorded from both eyes. (a,b) 
Overlays of the ERG recordings; green and blue lines represent recordings from combined suppression and replacement therapy (S+R) and control 
(C)-injected eyes, respectively. (c) Mean ERG b-wave amplitudes (μV). Green and blue columns represent values corresponding to S+R and control 
injected eyes, respectively. Error bars represent SD values and ***P < 0.001.Molecular Therapy  vol. 19 no. 4 apr. 2011  645
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suppression component, 6.0 × 108 vp of AAV-S (right eyes) or 
control AAV-C (left eyes) were subretinally injected into con-
tralateral  eyes.  Similarly,  to  test  the  replacement  component, 
1.8 × 1010 vp of AAV-R (right eyes) were subretinally injected 
whereas the fellow left eyes remained uninjected. Rod-isolated 
ERGs, performed 6 weeks postinjection were not significantly 
different; 60.5 ± 32.6 μV in AAV-S alone treated eyes compared 
to  68.1  ±  20.1 μV  (n  =  12)  in  control  eyes  (Supplementary 
Figure  S1a,c)  and  63.7  ±  38.6 μV  in  AAV-R  alone  treated 
eyes compared to 46.4 ± 17.9 μV (n = 10) in uninjected eyes 
(Supplementary Figure S1b,c) indicating that AAV-S alone or 
AAV-R alone did not provide benefit in P347S mice.
Notably,  the  benefit  observed  subsequent  to  subretinal 
delivery of the combined suppression and replacement therapy 
was also observed at the histological level. Six weeks postinjec-
tion, outer nuclear layer (ONL) thickness of sections from eyes 
treated with the mixture of AAV-R and AAV-S was 17.9 ± 3.4 μm 
compared to 13.3 ± 2.0 μm in sections from control eyes treated 
with AAV-C (P <0.0001, n = 5). Preservation of retinal struc-
ture  was  also  apparent  in  semithin  sections  (Supplementary 
Figure  S2a,b).  Transmission  electron  microscopy  (TEM)  of 
these  retinas  (n  =  3)  demonstrated  that  only  photoreceptor 
inner segments were present in control retinas whereas photo-
receptor inner segments and OS were abundant in AAV-S- and 
AAV-R-treated retinas (Supplementary Figure S2c,d). Due to 
the presence of OS, the distance between the ONL and the reti-
nal pigment epithelium (RPE) was greater in the treated eyes 
(Supplementary Figure S2).
Histological analysis at 20 weeks postinjection demonstrated 
a striking difference between combined suppression and replace-
ment-treated and control eyes. Whereas vestigial ERG responses 
were still recorded in some control eyes, the ONL had almost com-
pletely disappeared (and therefore ONL thickness was not mea-
surable) and rhodopsin protein was not detectable in the control 
eyes (Figure 4c,e). In contrast, the ONL in eyes treated with sup-
pression and replacement therapy contained 3–4 layers of photore-
ceptor nuclei (8.9 ± 1.2 μm thickness; n = 4, Figure 4d,f). Treated 
retinas were characterized by rhodopsin expression in both the 
ONL  and  the  photoreceptor  segment  layer  (Figure 4d,f). Note 
that enhanced green fluorescent protein (EGFP) tracer was only 
present in the RPE of the control eyes (as no photoreceptor layer 
remained; Figure 4c) whereas it was present in both RPE and ONL 
of the suppression- and replacement-treated retinas (Figure 4f). 
Differences in EGFP intensities between treated and control eyes 
were apparent in the whole mount retinas (Figure 4a,b) and were 
Ctr (20 weeks) S+R (20 weeks)
Figure  4  Immunohistochemical  analysis  of  rhodopsin  expression 
following  combined  suppression  and  replacement  therapy  20 
weeks postinjection. The right eyes of P5 P347S mice were subretinally 
injected with a mixture of (b,d, and f) 6.0 × 108 vp AAV-S and 1.8 × 1010 
vp AAV-R whereas the left eyes were injected with (a,c, and e) 6.0 × 108 
vp AAV-C. Note that AAV-S and AAV-C coexpress enhanced green flu-
orescent protein (EGFP). Eyes were fixed (n = 5), whole mounted for 
imaging,  then  cryosectioned  (12 μm)  and  processed  for  immunocy-
tochemistry  using  rhodopsin  primary  and  Cy3-conjugated  secondary 
antibodies. Nuclei were counterstained with DAPI. (a,b) Representative 
whole mounts. (c,d) Representative sections show rhodopsin labeling 
(red). (e,f) Rhodopsin (red), EGFP (green), and nuclear DAPI (blue) sig-
nals overlaid. *Photoreceptor segment layer; ONL, outer nuclear layer; 
INL, inner nuclear layer; GCL, ganglion cell layer; RPE, retinal pigment 
epithelium. Bars = 1 mm (a,b) and 25 μm (c–f).
Ctr (20 weeks) S+R (20 weeks)
Figure  5  ultrastructural  analysis  of  combined  suppression  and 
replacement-treated retinas 20 weeks postinjection. The right eyes 
of P5 P347S mice were subretinally injected with a mixture of (b,d) 
6.0 × 108 vp AAV-S and 1.8 × 1010 vp AAV-R whereas the left eyes were 
injected with (a,c) 6.0 × 108 vp AAV-C. Note that AAV-S and AAV-C 
coexpress enhanced green fluorescent protein (EGFP). Eyes were fixed, 
whole mounted, and transduced areas identified by EGFP fluorescence 
and excised. The excised retinal samples were postfixed and processed 
for transmission electron microscopy (TEM). Semi- and ultrathin sections 
were analyzed by (a,b) light microscopy or (c,d) TEM. Combined sup-
pression and replacement therapy resulted in preservation of rod pho-
toreceptor outer segments (OS), which extended to the retinal pigment 
epithelium (RPE; b and d). In contrast, in the control retina, only mem-
branous debris (*) was detected between the RPE and the inner nuclear 
layer (INL) whereas the outer nuclear layer (ONL) was not present (a,c). 
IS, inner segment layer, GCL, ganglion cell layer. Bars = 25 μm (a,b) and 
2 μm (c,d).646  www.moleculartherapy.org  vol. 19 no. 4 apr. 2011     
© The American Society of Gene & Cell Therapy
In vivo Gene Therapy for Retinitis Pigmentosa
independent of the transduction coverage (~40%). Semithin sec-
tions demonstrated significant photoreceptor rescue in the treated 
retinas (Figure 5a,b). At the ultrastructural level, well-preserved 
OS characterized the treated retina (Figure 5d) whereas only mem-
branous debris was present between the inner nuclear layer and the 
RPE (Figure 5c) in the control retina. High magnification TEM 
revealed individual photoreceptor segments, depicted in Figure 6. 
Short, degenerating OS with inflated and disorganized membrane 
disks were present in the control retina at 6 weeks postinjection 
(Figure 6a), whereas no photoreceptors were found at 20 weeks 
postinjection.  In  photoreceptor  cells  treated  with  AAV-S  and 
AAV-  R, the inner segments were attached to well-preserved OS 
with parallel layers of tightly stacked membrane disks at both 4 and 
20 weeks postinjection indicating substantial rescue of the photo-
sensitive OS (Figure 6b,c).
dIscussIon
The mutational heterogeneity inherent in many autosomal domi-
nantly inherited disorders represents a significant barrier to the 
development  of  therapies  focused  on  amending  the  primary 
genetic lesion. Suppression and replacement therapies represent 
a  means  to  circumvent  such  mutational  heterogeneity.  In  this 
study, the strategy has been explored for RHO-adRP. The results 
obtained clearly demonstrate that RNAi-suppression and codon-
modified replacement can be used in concert to provide functional 
benefit in the P347S mouse model of adRP. This should serve to 
promote the use of the approach for other dominantly inherited 
conditions such as RDS-linked adRP and COL7A1-linked epi-
dermolysis bullosa amongst others. In this regard, a suppression 
and replacement gene therapy for SOD-1-linked autosomal domi-
nantly inherited amyotrophic lateral sclerosis has recently been 
explored in mice.18 RNAi-based suppression and gene replace-
ment of SOD1 following AAV administration of a single vector 
was achieved as determined by RNA and protein assays. However, 
the histological and functional effects of AAV-delivered suppres-
sion and replacement were not studied.
Recent  clinical  trials  employing  AAV-mediated  subretinal 
delivery  of  an  RPE65  replacement  gene  for  Leber  congenital 
amaurosis have suggested that AAV is well tolerated in the human 
eye and have promoted the use of AAV for retinal gene delivery.2–7 
In addition, an inverse relationship between age of treatment and 
level of benefit was observed.5 Given the encouraging result from 
the  Leber  congenital  amaurosis  clinical  trials,  AAV  (2/5)  was 
adopted in the present study as the virus of choice to administer 
suppression and replacement therapies to P347S mice.
Although the clinical applications of AAV make it an attrac-
tive choice for gene delivery to the retina, transgene size con-
straints  associated  with  AAV  promoted  the  exploration  of 
viral mixtures consisting of two separate AAV suppression and 
replacement  vectors.  Using  reporter  viruses  (AAV-EGFP  and 
AAV-DsRed) initially, it was established that a substantial photo-
receptor coinfection with the two vector after a single subretinal 
injection of vector mixtures (Figure 1a–f). This encouraged the 
subsequent assessment of therapeutic coadministration of AAV-S 
and AAV-R in P347S mice. Of note, the dual vector strategy also 
allows a further level of control on the relative RHO suppression 
and replacement levels. To limit the probability of RHO suppres-
sion in the absence of RHO replacement, a greater amount of the 
AAV-R vector was employed. The dose of AAV-R chosen was 
the maximum possible given the AAV-R viral titer and one that 
had been previously shown to provide structural and functional 
benefit in the Rho−/− mouse.15 The dose of AAV-S used was the 
minimum required to achieve high levels of suppression.14 With 
regard to transgene size, there have been reports of transgenes 
of ~9 kb in AAV2/5 vectors.19 However, potential effects on titer 
and transgene expression remain unresolved.16 Three groups have 
since independently attempted to repeat packaging of large cas-
settes20–22 but their studies to date indicate that the packaging 
capacity of AAV is usually limited to about 5 kb. Hence, a dual 
vector approach for suppression and replacement was adopted in 
the present study.
Subretinal injections were undertaken at P5 in P347S mice to 
enable early administration of the gene therapy while minimiz-
ing surgical trauma that had previously been observed in younger 
animals, for example, in P0 and P1 injected eyes (data not shown). 
Significant  and  consistent  evidence  of  therapeutic  benefit  was 
obtained  using  both  electrophysical  and  histological  readouts. 
ERG comparisons between treated and control eyes at 6 weeks 
and 5 months demonstrated significantly improved responses in 
AAV-S and AAV-R dual-treated eyes (Figure 3a–c). The beneficial 
effects observed using ERG were also observed using histological 
analyses employing both light and electron microscopy. Retention 
of ONL (3–4 rows) was observed in treated P347S eyes 5 months 
subsequent to a single subretinal injection of AAV-S and AAV-  R, 
whereas in contrast, there were no remaining rows of photore-
ceptor nuclei in the ONL of control eyes (Figure 4). Likewise, 
Ctr (6 weeks) S+R (6 weeks) S+R (20 weeks)
Figure  6  Photoreceptor  morphology  rescue  following  combined 
suppression and replacement therapy. The right eyes of P5 P347S 
mice were subretinally injected with a mixture of 6.0 × 108 vp AAV-S 
and 1.8 × 1010 vp AAV-R (b and c; n = 3 and n = 1, respectively) whereas 
the left eyes were injected with 6.0 × 108 vp AAV-C (a; n = 4). Note 
that AAV-S and AAV-C coexpress enhanced green fluorescent protein 
(EGFP). (a,b) Six and (c) twenty weeks postinjection, eyes were fixed, 
whole mounted, and transduced areas identified by EGFP fluorescence 
and excised. The excised retinal samples were processed for transmission 
electron  microscopy  (TEM).  Combined  suppression  and  replacement 
therapy resulted in the preservation of rod photoreceptor outer seg-
ments (OS) with correctly formed membrane disks (b and c). In contrast 
in control retinas the rod photoreceptor inner segments (IS) attached to 
truncated OS with disorganized disks. CC, connecting cilium. Bars = 500 
and 100 nm (inserts).Molecular Therapy  vol. 19 no. 4 apr. 2011  647
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improved photoreceptor OS ultrastucture was detected by TEM 
in treated versus control P347S mouse eyes (Figures 5 and 6).
Although the AAV-S and AAV-R combination therapy was 
found to provide functional benefit in P347S mouse eyes when 
compared to control eyes, it was important to establish if either of 
these components alone provided the beneficial effect. Subretinal 
injection of AAV-S alone or AAV-R alone (using the same vector 
doses as employed in the AAV-S and AAV-R combination ther-
apy) did not provide significant therapeutic benefit in P347S mice 
when treated and control eyes were compared (Supplementary 
Figure S1a–c). Note that the relatively low dose of AAV-S used 
resulted in a modest but not significant reduction in ERG in the 
AAV-S treated eyes compared to eyes treated with AAV-C. In con-
trast, ERG responses in AAV-R, alone treated eyes were slightly 
enhanced when compared to control eyes but this difference did 
not reach statistical significance. Indeed, it was the combination 
of AAV-mediated suppression in conjunction with AAV-mediated 
replacement that was required to obtain benefit in this mouse 
model of RHO-adRP. It is worth noting that while the use of two 
separate AAV vectors for gene delivery is of direct relevance for 
suppression and replacement therapies where two components 
are essential, employing a dual-vector approach may also be of 
value where delivery of two synergistic therapies could poten-
tially augment benefit. One example may be the delivery of a gene 
replacement therapy together with a neurotrophic factor for some 
autosomal recessively inherited disorders23 amongst other com-
binations. Undoubtedly, the use of dual-vectors will be explored 
more extensively in the future in an attempt to optimize gene-
based therapeutics for many disorders. The results from the pres-
ent study validate the principle of a two-vector approach.
Suppression and replacement provides a means of correct-
ing the primary genetic defect and will be particularly relevant 
where the mutant protein drives the disease process. Alternative 
therapeutic approaches focused on modulating secondary effects 
associated with the disease are also being contemplated for adRP; 
many of these are focused on modulating secondary effects asso-
ciated with the disease. Some of these strategies have been evalu-
ated in rodent models of adRP and beneficial effects of the therapy 
observed. Such approaches include provision of neurotrophic fac-
tors and/or antiapoptotic factors, modulation of oxidative stress, 
cell replacement strategies, and reduction of protein aggregates.24–28 
Typically these approaches are being evaluated not solely for retinal 
degenerations but a broad range of neurodegenerative conditions. 
Indeed at times multivalent therapies involving a combination of 
strategies may be required to protect photoreceptors from degen-
eration precipitated by the presence of dominant mutations. The 
modes of action of different dominant RHO mutations can vary 
significantly and for some RHO mutations remain undetermined. 
These mechanisms may involve, for example, incorrect rhodopsin 
transport to the OSs, rhodopsin misfolding or may affect endo-
cytosis or protein stability.11 In principle, RHO suppression and 
replacement is relevant to RHO-linked adRP patients irrespective 
of the mode of action of a particular RHO mutation.
The potential power of viral vector-mediated RNAi as a thera-
peutic tool has been reviewed.29 In the present study, a strategy 
to correct the primary genetic defect in RHO-linked adRP was 
evaluated using two AAV viruses to deliver a dual-component 
therapy. RNAi-mediated suppression of RHO in conjunction with 
provision of an RNAi-resistant RHO replacement gene engineered 
using codon redundancy was found to provide functional benefit 
in the P347S mouse. This represents the first demonstration for 
any dominant condition that an AAV-delivered dual-component 
therapy (involving gene suppression and replacement) targeted 
at amending the primary defect can provide functional benefit. 
Employing RNAi in concert with replacement genes exploiting 
codon redundancy provides a means to overcome the mutational 
diversity associated with many autosomal dominant conditions. 
The results obtained provide the impetus to progress this thera-
peutic approach for RHO-adRP toward clinical trial.
MAterIAls And Methods
Vector construction and AAV production. RHO-targeting RNAi (shBB; 
target position nucleotide 254–274, accession no. NM_000539.2 and non-
targeting control RNAi (shNT; 5-TTCTCCCAACGAGTCACGTTTCAA 
GAGAACGTGACACGTTCGGAGAATTTTT-3)  were  cloned  into 
pAAV-MCS (Stratagene, La Jolla, CA) as described.14 shNT was guaranteed 
by the manufacturer (Qiagen, Venlo, The Netherlands) not to target any 
human or murine RNA sequences. shNT has previously been compared to 
other nontargeting control shRNAs and was shown to be equivalent (data 
not shown). A CMV promoter (CMV-P) including the CMV enhancer 
(CMVE;  accession  no.  EF550208)  and  the  SV40  polyadenylation  were 
used in both shRNA constructs to drive expression of an EGFP reporter 
gene  (accession  no.  U57608;  Clontech,  Mountain  View,  CA),  creating 
pAAV-S (shBB-EGFP) and pAAV-C (shNT-EGFP). Replacement human 
RHO complementary DNA sequence was constructed by modifying the 
wild-type human RHO sequence (accession no. NM_000539.2) at nucle-
otide 254–274 as follows 5′-ATAAATTTTTTGACCCTGTAT-3′ (altered 
bases underlined13). Replacement RHO (pAAV-R) was driven by a hybrid 
murine Rho promoter originally described as pAAV-BB24,15 which con-
tains a 1.7-kb mouse rhodopsin promoter (Rho-P) together with two con-
served Rho-P elements (element E, accession no. NT_005612, nucleotide 
35742513–35742578 and element B, accession no. AC142099.3, nucleotide 
24955-24880), a 0.4 kb fragment of the endogenous 3′-UTR, and a minimal 
polyadenylation signal.30 The EGFP (accession no. U57608; Clontech) and 
DsRed-Express2 genes (DsRed; accession no. FJ226077; Clontech) driven 
by a CMV promoter were also cloned into pAAV-MCS.
Constructs  were  packaged  into  helper-free  recombinant  AAV2/5 
viruses (AAV) as described,13 to generate AAV-shBB-EGFP (AAV-S), AAV-
shNT-EGFP (AAV-C), AAV-BB24 (AAV-R), AAV-EGFP, and AAV-DsRed. 
Briefly, the expression cassettes were transfected into human embryonic 
kidney-293 cells [ATCC (accession no. CRL-1573]) with pRep2/Cap531 and 
pHelper (Stratagene). Fifty 150-mm plates of confluent cells were transfected 
using polyethylenimine. Forty-eight hours after transfection, crude viral 
lysates were cleared and purified by cesium-gradient centrifugation. AAV-
containing  fractions  were  dialyzed  against  phosphate-buffered  saline. 
Genomic titers (vp/ml) were determined by qPCR.32
Animals and subretinal injections. Mutant transgenic RHO-Pro347Ser+/− 
Rho+/− (P347S14,33,34) and wild-type mice were used in this study. All ani-
mals were on a 129 S2/SvHsd (Harlan, Loughborough, UK) background. 
Mice were maintained under specific pathogen-free housing conditions. 
Subretinal  injections  were  carried  out  in  strict  compliance  with  the 
European Communities Regulations 2002 and 2005 (Cruelty to Animals 
Act)  and  the  Association  for  Research  in  Vision  and  Ophthalmology 
statement for the use of animals as described.13 Briefly, adult mice were 
anesthetized by intraperitoneal injection of medetomidine and ketamine 
(10 and 750 mg/10 g body weight, respectively). Pupils were dilated with 
1% cyclopentolate and 2.5% phenylephrine, and, using topical   anesthesia 
(Amethocaine),  a  small  puncture  was  made  in  the  sclera.  A  34-gauge 648  www.moleculartherapy.org  vol. 19 no. 4 apr. 2011     
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blunt-ended microneedle attached to a 10-μl Hamilton syringe was inserted 
through the puncture, and AAV was administered to the subretinal space. 
Following subretinal injection, an anesthetic reversing agent (100 mg/10 g 
body weight; Atipamezole Hydrochloride) was delivered by intraperito-
neal injection. Body temperature was maintained using a homeothermic 
heating device. Five-day-old mice were prepared for subretinal injection 
as described.35 Adult and 5-day-old mice were injected with 3 and 0.6 µl 
AAV, respectively. Typically between five and seven adult mice were used 
per group in order to obtain significance. However, between 10 and 17, 
5-day old mice per group were used, due to greater injection variability 
associated with small eye sizes. All animal studies have been approved by 
the authors’ institutional review board.
RNA extraction and qPCR analysis. Adult P347S mice (n = 6) were sub-
retinally injected with 6.0 × 108 vp AAV-S whereas fellow eyes received 
6.0 × 108 vp AAV-C. Retinas were harvested 2 weeks postinjection, trans-
duced (green) cells collected by fluorescence-activated cell sorting and 
RNA extracted from these cells.14 Levels of mutant RHO expression were 
determined  by  qPCR  using  human  RHO-specific  primers  previously 
described.13 Adult wild-type mice were subretinally injected with mixtures 
of 6.0 × 108 vp AAV-S and 1.8 × 1010 vp AAV-R (n = 7) or 6.0 × 108 vp 
AAV-C and 1.8 × 1010 vp AAV-R (n = 7). Two weeks postinjection eyes were 
harvested, RNA extracted from whole retinas and qPCRs, using human 
RHO-specific primers, performed to determine levels of replacement RHO 
expression as described.13 Adult wild-type mice were subretinally injected 
with 1.0 × 1010 vp of AAV-R (n = 8). Two weeks postinjection retinas were 
collected, total RNA extracted and levels of replacement RHO expression 
compared to levels of RHO mRNA in NHR mouse retinas by qPCR using 
human RHO-specific primers.13
ERG. ERG procedures have been described in detail.13,14 Briefly, intraperi-
toneal administration of ketamine and xylazine (16 and 1.6 mg/10 g body 
weight, respectively) were used for anesthesia. Pupils were dilated with 
1% cyclopentolate and 2.5% phenylephrine and eyes were maintained in 
a proptosed position throughout the examination. Reference and ground 
electrodes were positioned subcutaneously, ~1 mm from the temporal can-
thus and anterior to the tail, respectively. The ERG responses were recorded 
simultaneously from both eyes using goldwire electrodes (Roland Consult, 
Brandenburg,  Germany);  these  were  positioned  to  touch  the  central 
cornea of each eye. Corneal hydration and electrical contact were main-
tained by the application of Vidisic (Dr Mann Pharma, Berlin, Germany) 
to the cornea. Standardized flashes of light were presented to the mouse 
in a Ganzfeld bowl. Responses were analyzed using a RetiScan RetiPort 
electrophysiology unit (Roland Consulting). The protocol used was based 
on that approved by the International Clinical Standards Committee for 
human ERG. Rod-isolated responses were recorded using a dim white flash 
(−25 dB maximal intensity where maximal flash intensity was 3 candelas/
m2/s) presented in the dark-adapted state. The a-waves were measured 
from the baseline to the trough and b-waves from the baseline (standard 
convention). Following 10 minutes light adaptation (30 candelas/m2) cone 
responses were recorded to the standard flash presented at 0.5 and 10 Hz 
flicker against the rod suppressing background.
Microscopy and statistical analysis. Rhodopsin immunocytochemistry 
and fluorescence microscopy were performed as described.13 For immu-
nocytochemistry,  the  primary  rhodopsin  antibody  was  used  in  1:100 
dilution (courtesy of R. Molday). ONL thickness was measured in AAV 
transduced parts of the retina. Measurements were made at three points 
per section and three sections per retina. The sections were ~100 mm apart 
and within 300 mm of the optic nerve head. Measurements were made 
using the ruler tool in Photoshop (Adobe Systems Europe, Glasgow, UK). 
Procedures for TEM were previously described.15,36 Briefly, for tissue prep-
aration eyes were enucleated, fixed in 4% paraformaldehyde in phosphate-
buffered solution, and whole mounted. Using the EGFP tracer, EGFP+ 
areas from the central part of the retinas were excised and fixed in 2.5% 
glutaraldehyde in 0.1 mol/l cacodylate buffer (pH 7.3) for 2 hours at room 
temperature. Specimens were washed and fixed in buffered 2% osmium 
tetroxide, dehydrated, and embedded in araldite. Semi- and ultrathin sec-
tions were cut and ultrastructural analyses were performed using a Tecnai 
12 BioTwin transmission electron microscope (FEI, Eindhoven, NL).
Statistical analysis. Means and SD values of ERG, mRNA, and histology 
data sets were calculated. Student’s t-tests were used to determine statistical 
significance between corresponding data sets. Paired t-tests were applied 
to ERG data. In addition, Wilcoxon-signed rank tests were undertaken on 
mRNA and histology data sets and paired sign tests on ERG data sets to 
establish that statistical significance was maintained using nonparamet-
ric statistical models. Differences of P < 0.05 were considered statistically 
significant.
suPPleMentArY MAterIAl
Figure S1.  Rod-derived ERG following individual delivery of either 
suppression or replacement AAVs.
Figure S2.  Ultrastructural analysis of combined suppression and re-
placement treatment 6 weeks postinjection.
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